Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186606 | 0.98 | L3MBTL3 (0.34) | OPRL1L3MBTL3L3MBTL1MBTD1OPRM1 | |
| SCHEMBL4173229 | 0.83 | EBP (0.32) | KDM4EEBPDHCR7 | |
| SCHEMBL4186626 | 0.83 | IRAK4 (0.30) | — | |
| SCHEMBL4181149 | 0.81 | OPRL1 (0.38) | OPRL1L3MBTL3L3MBTL1 | |
| SCHEMBL4172642 | 0.81 | — | — | |
| SCHEMBL4172343 | 0.80 | IRAK4 (0.31) | OPRM1OPRK1 | |
| SCHEMBL13697604 | 0.68 | OPRL1 (0.37) | OPRL1L3MBTL3L3MBTL1OPRM1OPRK1 | |
| SCHEMBL737288 | 0.68 | L3MBTL3 (0.46) | OPRL1L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL19312856 | 0.68 | L3MBTL3 (0.46) | OPRL1L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL736033 | 0.68 | L3MBTL3 (0.46) | OPRL1L3MBTL3L3MBTL1MBTD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | OPRL1 38/4885L3MBTL3 3276/4885L3MBTL1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.